Centrus Energy Corp.
LEU
$111.97
+2.33%
Centrus Energy Corp. supplies nuclear fuel and related services to the nuclear power industry, operating through a Low-Enriched Uranium (LEU) segment that sells separative work units and uranium, and a Technical Solutions segment providing engineering, design, and manufacturing services to government and private customers, with the bulk of revenue generated domestically in the United States. The company occupies a uniquely strategic niche as the only Western (and specifically U.S.-licensed) producer of high-assay low-enriched uranium (HALEU), giving it a quasi-monopoly position in the fuel supply chain for the next generation of advanced reactors. The current investor narrative is dominated by the AI-driven nuclear power renaissance: Centrus has locked in landmark HALEU supply agreements with Antares Nuclear and Oklo, built a reported record ~$3.9 billion backlog, and holds a roughly $900 million government contract, all of which bulls argue secures years of future revenue. Against that, bears point to a deeply negative free cash flow profile, the looming expiration of its Russian enrichment contract, execution risk on capacity expansion, and a stock that has round-tripped from euphoric highs, making the debate one of transformational optionality versus near-term cash burn and valuation.…
LEU
Centrus Energy Corp.
$111.97
Related headlines
Investment Opinion: Should I buy LEU Today?
We rate Centrus Energy a Hold. The company's unique HALEU monopoly, $3.9 billion backlog, and $900 million government contract provide a powerful long-term growth narrative, but near-term cash burn and execution risks warrant caution. The analyst consensus is 'buy' with an average target of $225.15, implying 119.8% upside, but we believe the risk/reward is balanced at current levels.
Supporting evidence includes a 13.98% year-over-year revenue growth in Q2 2026, a net margin of 17.3%, and an operating margin of 11.2%, demonstrating underlying profitability. However, free cash flow is deeply negative at -$222.1 million, and the valuation remains rich with a trailing P/E of 56.1x and EV/EBITDA of 32.97x. The price-to-sales ratio of 9.72x is elevated for a company with volatile revenue. The implied upside to the average target is substantial, but the stock has already fallen 70% in a year, reflecting skepticism.
Key risks include the Russian contract expiration, which could create a revenue gap, and the need for significant capital to expand HALEU capacity. Execution missteps could lead to further downside. We would upgrade to Buy if the company demonstrates positive free cash flow and secures new long-term contracts that replace Russian revenue, or if the stock price falls below $80, improving the risk/reward. We would downgrade to Sell if free cash flow remains negative and the backlog fails to convert to revenue. Relative to its history and peers, the stock appears overvalued on near-term metrics but may be fairly valued on long-term growth prospects.
Sign up to view all
LEU 12-Month Price Forecast
We hold a neutral stance on Centrus Energy with medium confidence. The company's strategic position in HALEU and massive backlog are undeniable strengths, but the near-term financials are weak, with significant cash burn and a revenue cliff from the Russian contract. The valuation, while down from highs, still embeds optimistic assumptions. We would upgrade to bullish if Centrus demonstrates positive free cash flow and secures new long-term contracts, or if the stock price falls to a level that better compensates for the risks. Conversely, we would downgrade to bearish if execution disappoints or cash burn accelerates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centrus Energy Corp.'s 12-month outlook, with a consensus price target around $213.04 and implied upside of +90.3% versus the current price.
Average Target
$213.04
0 analysts
Implied Upside
+90.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$115 - $337
Analyst target range
Bulls vs Bears: LEU Investment Factors
The bull case for Centrus Energy rests on its unique strategic position as the only Western HALEU producer, a $3.9 billion backlog, and the AI-driven nuclear renaissance, which together offer transformational growth potential. However, the bear case is equally compelling: negative free cash flow of -$222 million, a revenue cliff from the expiring Russian contract, and a valuation that remains rich despite a 70% stock decline. Currently, the bear evidence appears stronger given the near-term cash burn and execution risks, but the most critical tension is whether Centrus can successfully ramp HALEU production and convert its backlog into sustainable cash flow before its legacy Russian revenue disappears. Resolution of this binary outcome will likely dictate the stock's trajectory.
Bullish
- Monopoly-like HALEU position: Centrus is the only U.S.-licensed producer of high-assay low-enriched uranium (HALEU), a critical fuel for advanced reactors. This quasi-monopoly is validated by landmark supply agreements with Antares Nuclear and Oklo, positioning Centrus as a linchpin in the Western nuclear fuel supply chain.
- Record $3.9B backlog and $900M government contract: The company has built a reported record backlog of approximately $3.9 billion, including a roughly $900 million government contract. This provides multi-year revenue visibility and underpins the bullish case for long-term growth.
- Strong revenue growth and profitability: Q2 2026 revenue grew 13.98% year-over-year to $176.1 million, with a net margin of 17.3% and operating margin of 11.2%. The company is profitable on a net income basis, with Q2 2026 net income of $16.8 million.
- Analyst consensus buy with significant upside: 18 analysts rate the stock a 'buy' with an average target price of $225.15, implying 119.8% upside from the current price of $102.45. The high target of $337 suggests even greater potential if execution remains on track.
Bearish
- Deeply negative free cash flow: Centrus reported negative free cash flow of -$222.1 million on a trailing twelve-month basis, highlighting significant cash burn. This raises concerns about funding ongoing operations and capacity expansion without further dilution or debt.
- Extreme valuation multiples: The stock trades at a trailing P/E of 56.1x, a price-to-sales ratio of 9.72x, and an EV/EBITDA of 32.97x, which are rich relative to historical norms and the broader market. The PEG ratio is negative due to low earnings, suggesting the valuation is stretched.
- Russian contract expiration risk: A significant portion of Centrus's near-term revenue comes from a Russian enrichment contract that is set to expire. Losing this contract could create a revenue cliff and undermine the company's financial performance until new HALEU contracts ramp up.
- Severe stock price decline and volatility: The stock has plummeted 70.2% over the past year and 62.4% year-to-date, with a max drawdown of -76.5% from its 52-week high of $402. This reflects extreme volatility (beta 1.536) and eroding investor confidence.
LEU Technical Analysis
Beta
1.54
1.54x market volatility
Max Drawdown
-77.4%
Largest decline past year
52-Week Range
$97-$402
Price range past year
Annual Return
-69.2%
Cumulative gain past year
| Period | LEU Return | S&P 500 |
|---|---|---|
| 1m | -20.2% | +0.9% |
| 3m | -36.7% | +4.1% |
| 6m | -45.8% | +7.2% |
| 1y | -69.2% | +12.4% |
| ytd | -58.9% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LEU Fundamental Analysis
Quarterly Revenue
$176100000.0B
2026-06
Revenue YoY Growth
+14.0%
YoY Comparison
Gross Margin
28.3%
Latest Quarter
Free Cash Flow
$-222100000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LEU Overvalued?
PE
56.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 1x~65x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.0x
Enterprise Value Multiple
Investment Risk Disclosure
Centrus faces significant financial and operational risks. The company burned $222.1 million in free cash flow over the trailing twelve months, far exceeding its $16.8 million Q2 net income, indicating that cash generation is deeply negative. With a debt-to-equity ratio of 1.59 and a current ratio of 5.59, liquidity appears adequate, but the cash burn could necessitate additional financing. Furthermore, revenue is concentrated in the LEU segment, and the expiration of the Russian enrichment contract poses a potential revenue cliff. Gross margin has been volatile, ranging from -5.7% in Q3 2025 to 45.0% in Q1 2025, reflecting earnings instability.
Market and competitive risks are pronounced. The stock's beta of 1.536 means it is highly sensitive to market swings, and its 70% decline over the past year underscores vulnerability to sector rotation and sentiment shifts. Valuation remains stretched: a trailing P/E of 56.1x and EV/EBITDA of 33.0x are premium multiples that assume flawless execution. Competition from other HALEU producers, such as Urenco and potentially new entrants, could erode Centrus's monopoly-like position. Regulatory changes or delays in advanced reactor deployment could also dampen demand. Recent news highlights the overdone rally on the Vistra DOE loan, with no evidence Vistra is a customer, suggesting market hype may be disconnected from fundamentals.
In a worst-case scenario, Centrus fails to ramp HALEU production on schedule, the Russian contract expires without replacement, and cash burn continues, forcing a dilutive equity raise. The stock could retest its 52-week low of $99.33, representing a 3.0% decline from the current price of $102.45, but given the max drawdown of -76.5%, a more severe decline to $50 or below is plausible if sentiment deteriorates. The analyst low target of $115 is above the current price, but if fundamentals worsen, the stock could overshoot to the downside. Investors could lose 50% or more from current levels in an adverse scenario.
FAQ
The key risks include: 1) Financial risk: negative free cash flow of -$222.1 million TTM and a debt-to-equity ratio of 1.59, which could necessitate dilutive financing. 2) Operational risk: execution challenges in scaling HALEU production and the expiration of the Russian enrichment contract, which could create a revenue cliff. 3) Market risk: high volatility with a beta of 1.536 and a 70% decline over the past year, reflecting sensitivity to sentiment and sector rotation. 4) Competitive risk: potential entry of other HALEU producers, such as Urenco, which could erode Centrus's monopoly-like position. These risks are ranked in order of severity, with financial and operational risks being the most immediate.
Our 12-month forecast presents three scenarios: Bull case (25% probability) with a target range of $225-$337, assuming successful HALEU ramp-up and new contracts; Base case (50% probability) with a target range of $115-$225, assuming steady progress but continued cash burn; and Bear case (25% probability) with a target range of $50-$115, assuming execution delays and a revenue cliff. The base case is most likely, hinging on the company's ability to manage cash burn and replace Russian revenue. The analyst average target of $225.15 aligns with our base case upper bound, but we note the stock could remain volatile.
LEU appears overvalued on near-term metrics. It trades at a trailing P/E of 56.1x, a price-to-sales ratio of 9.72x, and an EV/EBITDA of 32.97x, which are premium multiples relative to the broader market and its own history. The PEG ratio is negative due to low earnings, and free cash flow is negative. However, on a long-term basis, the valuation may be justified if the company successfully ramps HALEU production and converts its backlog into revenue. The market is pricing in significant future growth, so any execution misstep could lead to further multiple compression.
Whether LEU is a good buy depends on your risk tolerance and time horizon. The stock offers a compelling long-term growth story as the only Western HALEU producer, with a $3.9 billion backlog and analyst average target of $225.15, implying 119.8% upside. However, the company burned $222.1 million in free cash flow over the past year, and the Russian contract expiration poses a near-term revenue risk. The stock has fallen 70% in the past year, reflecting these concerns. For aggressive investors with a high risk tolerance, the potential reward may justify the risk, but conservative investors should wait for clearer execution and cash flow improvement.
LEU is more suitable for long-term investment, given its early-stage growth profile and the multi-year nature of its HALEU contracts. The company pays no dividend, and earnings visibility is limited by execution risks and the Russian contract expiration. The stock's high beta (1.536) and significant volatility make it unsuitable for short-term trading unless you are an experienced trader. We recommend a minimum holding period of 3-5 years to allow for the HALEU business to scale and for the backlog to convert into revenue. Investors should be prepared for continued volatility along the way.